Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

Market Cap	10.33B
Revenue (ttm)	709.13M
Net Income (ttm)	64.21M
Shares Out	405.71M
EPS (ttm)	0.16
PE Ratio	160.46
Forward PE	242.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,127,180
Average Volume	7,037,127
Open	25.71
Previous Close	25.76
Day's Range	25.43 - 25.87
52-Week Range	11.11 - 34.68
Beta	0.53
RSI	44.50
Earnings Date	Mar 20, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 470
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688319

Financial Performance

In 2024, SHA:688319's revenue was 588.86 million, an increase of 18.69% compared to the previous year's 496.12 million. Earnings were 20.76 million, an increase of 18.24%.